ID SIAT9_MOUSE Reviewed; 414 AA. AC O88829; B2RRS1; Q3TMT6; Q3TY01; Q91YF2; Q91YF3; Q9CZ65; Q9QWF8; Q9QWF9; DT 11-JUL-2002, integrated into UniProtKB/Swiss-Prot. DT 20-MAY-2008, sequence version 2. DT 24-JAN-2024, entry version 165. DE RecName: Full=Lactosylceramide alpha-2,3-sialyltransferase; DE EC=2.4.3.9 {ECO:0000269|PubMed:10092602, ECO:0000269|PubMed:12629211, ECO:0000269|PubMed:9875239}; DE AltName: Full=CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; DE AltName: Full=Ganglioside GM3 synthase; DE AltName: Full=ST3Gal V; DE Short=ST3GalV; DE AltName: Full=Sialyltransferase 9; GN Name=St3gal5; Synonyms=GM3S, Siat9; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Mus; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, CATALYTIC ACTIVITY, AND RP TISSUE SPECIFICITY. RC STRAIN=ICR; TISSUE=Brain; RX PubMed=9875239; DOI=10.1006/bbrc.1998.9768; RA Kono M., Takashima S., Liu H., Inoue M., Kojima N., Young-Choon L., RA Hamamoto T., Tsuji S.; RT "Molecular cloning and characterization of fifth type of beta-galactoside RT alpha-2,3-sialyltransferase (ST3Gal V; GM3 synthase)."; RL Biochem. Biophys. Res. Commun. 253:170-175(1998). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC STRAIN=C57BL/6J; TISSUE=Brain; RA Ishii A., Saito M.; RT "Mouse GM3 Synthase cDNA."; RL Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC STRAIN=C57BL/6J; RA Kapitonov D., Yu R.K.; RT "Combinatorial PCR in homologous cloning: cloning of GM3 synthase (ST-I)."; RL Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC STRAIN=C57BL/6J; TISSUE=Visual cortex; RX PubMed=16141072; DOI=10.1126/science.1112014; RA Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., RA Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K., RA Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J., RA Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R., RA Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T., RA Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A., RA Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., RA Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M., RA Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S., RA Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E., RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D., RA Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M., RA Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H., RA Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V., RA Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S., RA Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H., RA Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N., RA Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F., RA Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., RA Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., RA Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C., RA Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y., RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S., RA Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K., RA Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R., RA van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H., RA Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M., RA Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C., RA Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S., RA Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K., RA Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M., RA Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C., RA Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A., RA Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.; RT "The transcriptional landscape of the mammalian genome."; RL Science 309:1559-1563(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 52-414, FUNCTION, CATALYTIC ACTIVITY, AND RP TISSUE SPECIFICITY. RC STRAIN=BALB/cJ; RX PubMed=10092602; DOI=10.1074/jbc.274.14.9271; RA Fukumoto S., Miyazaki H., Goto G., Urano T., Furukawa K., Furukawa K.; RT "Expression cloning of mouse cDNA of CMP-NeuAc: lactosylceramide alpha2,3- RT sialyltransferase, an enzyme that initiates the synthesis of RT gangliosides."; RL J. Biol. Chem. 274:9271-9276(1999). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 106-414. RC STRAIN=ICR; TISSUE=Brain; RA Shuichi T.; RL Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases. RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND DISRUPTION PHENOTYPE. RX PubMed=12629211; DOI=10.1073/pnas.0635898100; RA Yamashita T., Hashiramoto A., Haluzik M., Mizukami H., Beck S., Norton A., RA Kono M., Tsuji S., Daniotti J.L., Werth N., Sandhoff R., Sandhoff K., RA Proia R.L.; RT "Enhanced insulin sensitivity in mice lacking ganglioside GM3."; RL Proc. Natl. Acad. Sci. U.S.A. 100:3445-3449(2003). RN [9] RP FUNCTION (MICROBIAL INFECTION), AND DISRUPTION PHENOTYPE. RC STRAIN=C57BL/6J; RX PubMed=16115873; DOI=10.1074/jbc.m507596200; RA Tsukamoto K., Kohda T., Mukamoto M., Takeuchi K., Ihara H., Saito M., RA Kozaki S.; RT "Binding of Clostridium botulinum type C and D neurotoxins to ganglioside RT and phospholipid. Novel insights into the receptor for clostridial RT neurotoxins."; RL J. Biol. Chem. 280:35164-35171(2005). CC -!- FUNCTION: (Microbial infection) Gangliosides GD1b and GT1b (derived CC from GM3) may serve as receptors for some C.botulinum neurotoxins CC (minimally types BoNT/A, B, C) (PubMed:16115873). CC {ECO:0000305|PubMed:16115873}. CC -!- FUNCTION: Transfers the sialyl group (N-acetyl-alpha-neuraminyl or CC NeuAc) from CMP-NeuAc to the non-reducing terminal galactose (Gal) of CC glycosphingolipids forming gangliosides (important molecules involved CC in the regulation of multiple cellular processes, including cell CC proliferation and differentiation, apoptosis, embryogenesis, CC development, and oncogenesis) (PubMed:9875239, PubMed:10092602, CC PubMed:12629211). Mainly involved in the biosynthesis of ganglioside CC GM3 but can also use different glycolipids as substrate acceptors such CC as D-galactosylceramide (GalCer), asialo-GM2 (GA2) and asialo-GM1 CC (GA1), although less preferentially than beta-D-Gal-(1->4)-beta-D-Glc- CC (1<->1)-Cer (LacCer) (By similarity). {ECO:0000250|UniProtKB:Q9UNP4, CC ECO:0000269|PubMed:10092602, ECO:0000269|PubMed:12629211, CC ECO:0000269|PubMed:9875239}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + CMP-N- CC acetyl-beta-neuraminate = a ganglioside GM3 (d18:1(4E)) + CMP + H(+); CC Xref=Rhea:RHEA:18417, ChEBI:CHEBI:15378, ChEBI:CHEBI:17950, CC ChEBI:CHEBI:57812, ChEBI:CHEBI:60065, ChEBI:CHEBI:60377; EC=2.4.3.9; CC Evidence={ECO:0000269|PubMed:10092602, ECO:0000269|PubMed:12629211, CC ECO:0000269|PubMed:9875239}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18418; CC Evidence={ECO:0000305|PubMed:10092602, ECO:0000305|PubMed:12629211, CC ECO:0000305|PubMed:9875239}; CC -!- CATALYTIC ACTIVITY: CC Reaction=CMP-N-acetyl-beta-neuraminate + ganglioside GA2 CC (d18:1(4E)/18:0) = CMP + ganglioside GM2 (d18:1(4E)/18:0) + H(+); CC Xref=Rhea:RHEA:41776, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, CC ChEBI:CHEBI:60377, ChEBI:CHEBI:78485, ChEBI:CHEBI:78486; CC Evidence={ECO:0000250|UniProtKB:Q9UNP4}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41777; CC Evidence={ECO:0000250|UniProtKB:Q9UNP4}; CC -!- CATALYTIC ACTIVITY: CC Reaction=beta-D-Gal-(1<->1')-Cer + CMP-N-acetyl-beta-neuraminate = CMP CC + H(+) + N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl- CC (1<->1')-ceramide; Xref=Rhea:RHEA:41780, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:57812, ChEBI:CHEBI:60377, ChEBI:CHEBI:82643, CC ChEBI:CHEBI:143593; Evidence={ECO:0000250|UniProtKB:Q9UNP4}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41781; CC Evidence={ECO:0000250|UniProtKB:Q9UNP4}; CC -!- CATALYTIC ACTIVITY: CC Reaction=CMP-N-acetyl-beta-neuraminate + ganglioside GA1 CC (d18:1(4E)/18:0) = CMP + ganglioside GM1 (d18:1(4E)/18:0) + H(+); CC Xref=Rhea:RHEA:41784, ChEBI:CHEBI:15378, ChEBI:CHEBI:57812, CC ChEBI:CHEBI:60377, ChEBI:CHEBI:73110, ChEBI:CHEBI:78484; CC Evidence={ECO:0000250|UniProtKB:Q9UNP4}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41785; CC Evidence={ECO:0000250|UniProtKB:Q9UNP4}; CC -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000305}; Single- CC pass type II membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=O88829-1; Sequence=Displayed; CC Name=2; CC IsoId=O88829-2; Sequence=VSP_033689; CC -!- TISSUE SPECIFICITY: Mainly expressed in brain, and then testis, heart CC and liver, almost all tissues showed some levels of the gene CC expression. {ECO:0000269|PubMed:10092602, ECO:0000269|PubMed:9875239}. CC -!- DISRUPTION PHENOTYPE: Mice are viable and fertile, and do not show any CC obvious abnormality apart from an increased sensitivity to insulin CC (PubMed:12629211). The major brain gangliosides derived from GM3 (GM1a, CC GD1a, GD1b, and GT1b) are missing (PubMed:12629211). CC {ECO:0000269|PubMed:12629211}. CC -!- DISRUPTION PHENOTYPE: (Microbial infection) Cerebellar granule cells CC are no longer susceptible to C.botulinum neurotoxin type C (BoNT/C), CC and syntaxin, the BoNT/C target, is not degraded. Cells remain CC susceptible to neurotoxins C.botulinum neurotoxin types CD and D CC (BoNT/CD and BoNT/D, botD) (PubMed:16115873). Knockout mice survive 6 CC times longer when injected intravenously with BoNT/C; the knockout has CC no effects on time of survival for BoNT/CD and BoNT/D CC (PubMed:16115873). {ECO:0000269|PubMed:16115873}. CC -!- SIMILARITY: Belongs to the glycosyltransferase 29 family. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF66147.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA33491.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAA76467.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAB28571.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=BAE34763.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAA75235.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAA75236.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAC79655.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase; Note=ST3Gal V; CC URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_mou_646"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Y15003; CAA75235.1; ALT_INIT; mRNA. DR EMBL; Y15003; CAA75236.1; ALT_INIT; mRNA. DR EMBL; AB018048; BAA33491.1; ALT_INIT; mRNA. DR EMBL; AF119416; AAF66147.1; ALT_INIT; mRNA. DR EMBL; AK012961; BAB28571.1; ALT_INIT; mRNA. DR EMBL; AK159000; BAE34763.1; ALT_INIT; mRNA. DR EMBL; AK165726; BAE38355.1; -; mRNA. DR EMBL; BC138557; AAI38558.1; -; mRNA. DR EMBL; BC138559; AAI38560.1; -; mRNA. DR EMBL; AB013302; BAA76467.1; ALT_INIT; mRNA. DR EMBL; Y18022; CAC79654.1; -; Genomic_DNA. DR EMBL; Y18023; CAC79655.1; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS20237.1; -. [O88829-1] DR PIR; JE0364; JE0364. DR RefSeq; NP_001030305.1; NM_001035228.2. [O88829-1] DR RefSeq; NP_035505.2; NM_011375.3. DR RefSeq; XP_006505880.1; XM_006505817.3. DR AlphaFoldDB; O88829; -. DR SMR; O88829; -. DR BioGRID; 203247; 1. DR ELM; O88829; -. DR STRING; 10090.ENSMUSP00000070414; -. DR SwissLipids; SLP:000000752; -. DR SwissLipids; SLP:000000759; -. DR CAZy; GT29; Glycosyltransferase Family 29. DR GlyConnect; 2454; 4 N-Linked glycans (1 site). DR GlyCosmos; O88829; 3 sites, 4 glycans. DR GlyGen; O88829; 3 sites, 4 N-linked glycans (1 site). DR iPTMnet; O88829; -. DR PhosphoSitePlus; O88829; -. DR SwissPalm; O88829; -. DR MaxQB; O88829; -. DR PaxDb; 10090-ENSMUSP00000070414; -. DR PeptideAtlas; O88829; -. DR ProteomicsDB; 261398; -. [O88829-1] DR ProteomicsDB; 261399; -. [O88829-2] DR Pumba; O88829; -. DR Antibodypedia; 31972; 174 antibodies from 25 providers. DR DNASU; 20454; -. DR Ensembl; ENSMUST00000069994.11; ENSMUSP00000070414.5; ENSMUSG00000056091.13. [O88829-1] DR GeneID; 20454; -. DR KEGG; mmu:20454; -. DR UCSC; uc009chy.2; mouse. [O88829-1] DR AGR; MGI:1339963; -. DR CTD; 8869; -. DR MGI; MGI:1339963; St3gal5. DR VEuPathDB; HostDB:ENSMUSG00000056091; -. DR eggNOG; KOG2692; Eukaryota. DR GeneTree; ENSGT00940000157929; -. DR InParanoid; O88829; -. DR OrthoDB; 5404317at2759; -. DR PhylomeDB; O88829; -. DR TreeFam; TF352819; -. DR BRENDA; 2.4.99.9; 3474. DR Reactome; R-MMU-4085001; Sialic acid metabolism. DR BioGRID-ORCS; 20454; 5 hits in 80 CRISPR screens. DR ChiTaRS; St3gal5; mouse. DR PRO; PR:O88829; -. DR Proteomes; UP000000589; Chromosome 6. DR RNAct; O88829; Protein. DR Bgee; ENSMUSG00000056091; Expressed in granulocyte and 249 other cell types or tissues. DR ExpressionAtlas; O88829; baseline and differential. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0047291; F:lactosylceramide alpha-2,3-sialyltransferase activity; ISS:UniProtKB. DR GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW. DR GO; GO:0006486; P:protein glycosylation; IBA:GO_Central. DR Gene3D; 3.90.1480.20; Glycosyl transferase family 29; 1. DR InterPro; IPR001675; Glyco_trans_29. DR InterPro; IPR038578; GT29-like_sf. DR PANTHER; PTHR13713:SF60; LACTOSYLCERAMIDE ALPHA-2,3-SIALYLTRANSFERASE; 1. DR PANTHER; PTHR13713; SIALYLTRANSFERASE; 1. DR Pfam; PF00777; Glyco_transf_29; 1. DR Genevisible; O88829; MM. PE 1: Evidence at protein level; KW Alternative splicing; Disulfide bond; Glycoprotein; Glycosyltransferase; KW Golgi apparatus; Lipid metabolism; Membrane; Reference proteome; KW Signal-anchor; Transferase; Transmembrane; Transmembrane helix. FT CHAIN 1..414 FT /note="Lactosylceramide alpha-2,3-sialyltransferase" FT /id="PRO_0000149303" FT TOPO_DOM 1..65 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT TRANSMEM 66..86 FT /note="Helical; Signal-anchor for type II membrane protein" FT /evidence="ECO:0000255" FT TOPO_DOM 87..414 FT /note="Lumenal" FT /evidence="ECO:0000255" FT CARBOHYD 235 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 279 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 389 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 194..352 FT /evidence="ECO:0000250" FT VAR_SEQ 1..26 FT /note="MHTEAVGGAARRPQKLRSQAAAPACR -> MGAPGELRRCGRGAA (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:9875239" FT /id="VSP_033689" FT CONFLICT 139 FT /note="N -> K (in Ref. 4; BAE34763)" FT /evidence="ECO:0000305" FT CONFLICT 183 FT /note="P -> S (in Ref. 1; CAA75235/CAA75236)" FT /evidence="ECO:0000305" FT CONFLICT 232 FT /note="H -> Y (in Ref. 4; BAE34763)" FT /evidence="ECO:0000305" SQ SEQUENCE 414 AA; 47360 MW; 3BC5AEE20D7627DD CRC64; MHTEAVGGAA RRPQKLRSQA AAPACRAMPS EFTSAKLRSD CSRTSLQWYT RTQHKMRRPS LLIKDICKCT LVAFGVWLLY ILILNYTAEE CDMKRMHYVD PDRIKRAQSY AQEVLQKECR PRYAKTAMAL LFEDRYSINL EPFVQKVPTA SEAELKYDPP FGFRKFSSKV QSLLDMLPEH DFPEHLRAKA CKRCVVVGNG GILHGLELGH ALNQFDVVIR LNSAPVEGYS EHVGNKTTIR MTYPEGAPLS DVEYYANDLF VTVLFKSVDF KWLQAMVKNE SLPFWVRLFF WKQVAEKVPL QPKHFRILNP VIIKETAFDI LQYSEPQSRF WGHDKNIPTI GVIAVVLATH LCDEVSLAGF GYDLSQPRTP LHYFDSQCMG AMHWQVMHNV TTETKFLLKL LKEGVVEDLS GGIH //